AFT — AFT Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- NZ$482.38m
- NZ$525.04m
- NZ$254.71m
Brief: AFT Pharmaceuticals Says Continue To Expect To Declare A Dividend For FY24
Brief: Hikma Expands Agreement With AFT Pharmaceuticals For Commercialisation Of Combogesic®
Develop New Product Candidate For Vulvar Lichen Sclerosus
Brief: AFT Pharmaceuticals Says FY24 Result Will Be Significantly Influenced By US Licensing Income
Brief: Aft Pharmaceuticals Broadens R+D Pipeline With New Product Candidate
France keeps 2024 bond issuance steady at 285 bln euros
Brief: AFT Pharmaceuticals Says HY Net Profit After Tax Increases 17% To NZ$1.8 Million
NZ's AFT Pharmaceuticals eyes best day in 5 weeks on HY results
Brief: Aft Pharmaceuticals Says Aft's Crystaderm Antiseptic Approved For Sale In China
Hyloris Pharma wins US FDA approval for pain treatment
Brief: AFT Pharmaceuticals Says Welcome US FDA Approval For Sale Of Maxigesic IV
New Zealand's AFT Pharmaceuticals jumps on U.S. FDA approval for pain relief drug
New Zealand's AFT Pharmaceuticals jumps on U.S. FDA pain relief drug approval
Brief: AFT Pharmaceuticals Updates On AFT Orphan Pharmaceuticals Judgment
NZ's AFT Pharmaceuticals rises on licensing deal for epilepsy therapy
Brief: Aft Pharmaceuticals Signs New Licensing Agreement For Zeneo® Midazolam
Brief: AFT Pharmaceuticals Extends E-commerce Presence Into Amazon U.S.
NZ's AFT Pharmaceuticals hits over 2-mnth high on upbeat FY24 outlook
Brief: AFT Pharmaceuticals Posts FY Net Profit After Tax Of NZ$10.7 Million